Table 3.

Risks of adverse breast cancer outcomes among monotherapy users of antihypertensive medications

All womenSBCERecurrence
n = 2494n = 84n = 65
Medication use after breast cancer diagnosisn (%)an (%)aHRb (95% CI)n (%)aHRb (95% CI)
ACEIs610 (24.5)17 (20.2)0.83 (0.41–1.67)13 (20.0)0.78 (0.35–1.70)
ARBs310 (12.4)15 (17.9)1.31 (0.64–2.70)11 (16.9)1.22 (0.54–2.75)
BBs642 (25.7)17 (20.2)0.89 (0.45–1.77)12 (18.5)0.73 (0.33–1.57)
CCBs430 (17.2)17 (20.2)1.12 (0.57–2.20)13 (20.0)0.99 (0.47–2.09)
Diuretics502 (20.1)18 (21.4)Reference16 (24.6)Reference
  • aCounts and percentages reflect ever use after cancer diagnosis, which was defined as having at least one prescription of a given drug after the initial cancer diagnosis while the Cox models defined ever use as time-varying such that at risk time before one becomes a user contributes to the nonuser category.

  • bHR adjusted for age at diagnosis, year of diagnosis, AJCC stage, ER/PR status, receipt of complete first course treatment, receipt of any chemotherapy, use of adjuvant hormone treatment (time-varying), diabetes at breast cancer diagnosis.

  • cMonotherapy users were defined in a time-varying fashion such that women entered the cohort on the day they first filled a prescription of antihypertensive medications and left the cohort on the day they started another antihypertensive medication. Users of each class were compared to diuretics users in separate time-varying Cox models.